Benzinga | Jan 12, 2022 05:33AM EST

Piper Sandler Downgrades Biogen to Neutral, Lowers Price Target to $216

Piper Sandler analyst Christopher Raymond downgrades Biogen (NASDAQ:BIIB) from Overweight to Neutral and lowers the price target from $362 to $216.